UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):February 2, 2005 (February 1, 2005)
GTx, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 005-79588 | | 62-1715807 |
| (State or other jurisdiction of | | (Commission | | (I.R.S. Employer |
| incorporation or organization) | | File Number) | | Identification No.) |
3 N. Dunlap Street
3rd Floor, Van Vleet Building
Memphis, Tennessee 38163
(901) 523-9700
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
_____________________________________________
(Former name or former address, if changed since last report)
TABLE OF CONTENTS
ITEM 8.01 Other Events.
On February 1, 2005, GTx, Inc. announced that it has initiated a Phase I clinical trial for ostarine, GTx’s second selective androgen receptor modulator (SARM) compound to be tested in clinical trials. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
ITEM 9.01 Financial Statements and Exhibits.
(c) Exhibits
| | | | | |
| Exhibit | | |
| Number | | Description |
| | 99.1 | | | Press Release issued by GTx, Inc. dated February 1, 2005 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | GTx, Inc.
| |
| Date: February 2, 2005 | By: | /s/ Henry P. Doggrell | |
| | | Name: | Henry P. Doggrell | |
| | | Title: | Vice President, General Counsel/Secretary | |
| |
